Eliquis

(Apixaban)

ApprovedSmall molecule

Apixaban is used to prevent blood clots and reduce the risk of stroke in people with irregular heart rhythm, and to treat or prevent blood clots in the legs and lungs after surgery or in certain medical conditions.[2] Eliquis is currently approved and in use across 43 indications[4].[1]

Eliquis is one of 580 small molecule programs targeting Coronary Artery Disease. It is currently in Approved.

Indications

265

Total Trials

Active Trials

579

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[4][1]

Indication

Coronary Artery DiseaseActive, not recruiting

CalcificationActive, not recruiting

Cirrhosis of LiverApproved

Atrial FlutterApproved

Venous ThromboembolismCompleted

Thrombotic DiseaseActive, not recruiting

ThrombocytopeniaTerminated

Venous ThrombosisTerminated

HemorrhageApproved

Acute Myocardial InfarctionRecruiting

Coronary Artery DiseaseApproved

Active, not recruiting

CalcificationApproved

Active, not recruiting

Cirrhosis of LiverApproved

Approved

Atrial FlutterApproved

Approved

Venous ThromboembolismApproved

Completed

Thrombotic DiseaseApproved

Active, not recruiting

ThrombocytopeniaPhase 2

Terminated

Venous ThrombosisApproved

Terminated

HemorrhageApproved

Approved

Acute Myocardial InfarctionApproved

Recruiting

Showing 10 of 42 indications

Competition

Competitive Landscape

309 competitors in COVID-19

#DrugCompanyPhaseTrials

Eliquis

Bristol-Myers Squibb

Approved

7 2

Aimovig

Amgen

Preclinical

1 3

Aldactone

Pfizer

Preclinical

1 4

Nexavar

Bayer

Preclinical

1 5

Stivarga

Bayer

Preclinical

1 6

Activella

Calciferol

Angiomax

BBaxter Healthcare Corporation

Preclinical

2 9

Tricor

JJagotec

Preclinical

1 10

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

N/ARecruiting

Hematologic Malignancies

NCT07270263

Post-ApprovalRecruiting

Prophylaxis

NCT05735639

Phase 3Active, not recruiting

Portal Hypertension

NCT04007289

Q1 2027

N/ARecruiting

Portal Vein Thrombosis

NCT07461545

Q2 2027

Phase 3Recruiting

Stroke

NCT03907046

Recruiting

Atrial Fibrillation

NCT07458191

Clinical

Trials by Indication[1]

Atrial Fibrillation43 trials

The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Atrial Fibrillation

Active, not recruiting·HHerlev and Gentofte Hospital·Phase 4·NCT03129490·11,000 enrolled

Stroke Prevention In Ischemic Stroke With Covert Atrial Fibrillation

Not yet recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 4·NCT06486792·1,148 enrolled

A Phase 2 Study To Evaluate The Safety Of Apixaban In Atrial Fibrillation

Completed· Pfizer logo

Pfizer·Phase 2·NCT00787150·222 enrolled

Show 40 more trials

Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation

Completed·PPopulation Health Research Institute·Phase 4·NCT01938248·4,012 enrolled

Trial to Evaluate Anticoagulation Therapy in Hemodialysis Patients With Atrial Fibrillation

Completed·—·Phase 4·NCT02942407·154 enrolled

Apixaban During Atrial Fibrillation Catheter Ablation: Comparison to Vitamin K Antagonist Therapy

Completed·AAtrial Fibrillation Network·Phase 4·NCT02227550·676 enrolled

A Phase III Study of Apixaban in Patients With Atrial Fibrillation

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT00496769·6,421 enrolled

Apixaban in the Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in Real-Life Setting in France

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb··NCT02714855·2,081 enrolled

Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT00412984·20,976 enrolled

Compare Apixaban and Vitamin-K Antagonists in Patients With Atrial Fibrillation (AF) and End-Stage Kidney Disease (ESKD)

Completed·AAtrial Fibrillation Network·Phase 3·NCT02933697·108 enrolled

Safety and Effectiveness of Apixaban in Very Elderly Patients With Non-valvular Atrial Fibrillation (NVAF) Compared to Warfarin Using Administrative Claims Data

Completed· Pfizer logo

Pfizer··NCT05438888·77,814 enrolled

Study to Gather Information About the Proper Dosing of the Oral FXIa Inhibitor BAY 2433334 and to Compare the Safety of the Study Drug to Apixaban, a Non-vitamin K Oral Anticoagulant (NOAC) in Patients With Irregular Heartbeat (Atrial Fibrillation) That Can Lead to Heart-related Complications.

Completed· Bayer logo

Bayer·Phase 2·NCT04218266·755 enrolled

Study Of The Blood Thinner, Apixaban, For Patients Who Have An Abnormal Heart Rhythm (Atrial Fibrillation) And Expected To Have Treatment To Put Them Back Into A Normal Heart Rhythm (Cardioversion)

Completed· Pfizer logo

Pfizer·Phase 4·NCT02100228·1,500 enrolled

A Study of Apixaban in Patients With Atrial Fibrillation, Not Caused by a Heart Valve Problem, Who Are at Risk for Thrombosis (Blood Clots) Due to Having Had a Recent Coronary Event, Such as a Heart Attack or a Procedure to Open the Vessels of the Heart

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 4·NCT02415400·4,614 enrolled

Replication Of An Early Evaluation Of 30-Day Readmissions Among Nonvalvular Atrial Fibrillation Patients Treated With Dabigatran, Rivaroxaban, Apixaban, or Warfarin In The U.S

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb··NCT02769078·14,201 enrolled

An Observational Study (Called RETAF-PS) Using a Patient Survey to Learn More About Treatment Outcomes in Patients With Irregular and Often Rapid Heartbeat (Atrial Fibrillation) Treated With Apixaban in a Real World Setting

Completed· Bayer logo

Bayer··NCT05471830·600 enrolled

ORal anticoaGulants in diAbetic and Nondiabetic Patients With nOn-valvular Atrial fibrillatioN (ORGANON)

Completed·UUniversity of Pavia·Phase 4·NCT02935855·300 enrolled

Strategies for the Management of Atrial Fibrillation in patiEnts Receiving Dialysis

Completed·UUnity Health Toronto·Phase 2·NCT03987711·151 enrolled

Trial of Apixaban vs Warfarin in Reducing Rate of Cognitive Decline, Silent Cerebral Infarcts and Cerebral Microbleeds in Patients With Atrial Fibrillation

Terminated·MMayo Clinic·Phase 3·NCT03839355·34 enrolled

A Study to Learn How Well the Study Treatment Asundexian Works and How Safe it is Compared to Apixaban to Prevent Stroke or Systemic Embolism in People With Irregular and Often Rapid Heartbeat (Atrial Fibrillation), and at Risk for Stroke

Terminated· Bayer logo

Bayer·Phase 3·NCT05643573·14,830 enrolled

Study to Gather Information About the Safety of Oral Anticoagulation Drugs and How Well These Drugs Work in Real World for Patients With Non-valvular Atrial Fibrillation (Irregularly Heart Beats Which is Not Caused by a Heart Valve Problem)

Completed· Bayer logo

Bayer··NCT04249401·134,897 enrolled

APIXABAN in the Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in Real-Life Setting in France SNIIRAM Study

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb··NCT02640222·321,501 enrolled

Efficacy and Safety of MAA868 in Patients With Atrial Fibrillation

Withdrawn· Novartis logo

Novartis·Phase 2·NCT03398434

Predictive Factors for Response to New Oral Anticoagulants in the Treatment of Non-valvular Atrial Fibrillation..

Unknown status·FFundación de Investigación Biomédica - Hospital Universitario de La Princesa··NCT04297150·700 enrolled

Comparison of Efficacy and Safety Among Dabigatran, Rivaroxaban, and Apixaban in Non-Valvular Atrial Fibrillation

Unknown status·NNational Cheng-Kung University Hospital·Phase 4·NCT02666157·3,672 enrolled

Real-world Comparative Effectiveness of Stroke Prevention in Patients With Atrial Fibrillation Treated With Factor Xa Non-vitamin-K Oral Anticoagulants (NOACs) vs. Phenprocoumon

Completed· Bayer logo

Bayer··NCT03563937·64,920 enrolled

Comparison of Brain Perfusion in Rhythm Control and Rate Control of Persistent Atrial Fibrillation

Unknown status·YYonsei University·N/A·NCT02633774·200 enrolled

A Study to Learn About the Effects of Medicines That Help in Thinning the Blood in People With Atrial Fibrillation (AF) Between 2016 and 2020 in France

Completed· Pfizer logo

Pfizer··NCT05838664·2,140,403 enrolled

Apixaban Safety and Therapy Adherence in Patients With Atrial Fibrillation

Recruiting·BBosnalijek D.D··NCT07458191·800 enrolled

A Real-World Comparison of Safety and Effectiveness of Novel Oral Anti-Coagulant (NOAC) Naïve and Warfarin Naïve Non-Valvular Atrial Fibrillation (NVAF) Patients With Medicare Advantage Coverage

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb··NCT03189069·36,000 enrolled

Real-World Comparative Observational Study in Non-Valvular Atrial Fibrillation Patients Using Oral Anticoagulants

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb··NCT02754154·321,182 enrolled

Study to Evaluate the Use of Direct Oral Anticoagulants in UK Clinical Practice For Patients With a First Stroke Attributable to Nonvalvular Atrial Fibrillation

Completed· Daiichi Sankyo logo

Daiichi Sankyo··NCT05262322·234 enrolled

Apixaban Drug Utilization Study In Stroke Prevention In Atrial Fibrillation (Spaf)

Completed· Pfizer logo

Pfizer··NCT03441633·51,690 enrolled

Safety and Effectiveness of Apixaban Compared to Warfarin in Secondary Prevention in Patients With Atrial Fibrillation

Completed· Pfizer logo

Pfizer··NCT05321810·193,565 enrolled

Left Atrial Appendage CLOSURE in Patients With Atrial Fibrillation Compared to Medical Therapy

Completed·—·Phase 4·NCT03463317·912 enrolled

Prospective Monitoring of Non-Vitamin K Oral Anticoagulants in Older Adults With Atrial Fibrillation and Frailty

Unknown status·—··NCT04878497·1,000,000 enrolled

Assessment of an Education and Guidance Programme for Eliquis Adherence in Non-Valvular Atrial Fibrillation (AEGEAN)

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 4·NCT01884350·1,217 enrolled

Apixaban After Anticoagulation-associated Intracerebral Haemorrhage in Patients With Atrial Fibrillation

Completed·UUMC Utrecht·Phase 2·NCT02565693·101 enrolled

Oral Anticoagulant Discontinuation, Adherence Patterns, Hospitalizations and Costs in Non-Valvular Atrial Fibrillation (NVAF) Patients

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb··NCT02792335·28,000 enrolled

PREvention of STroke in Intracerebral haemorrhaGE Survivors With Atrial Fibrillation

Completed·IImperial College London·Phase 3·NCT03996772·319 enrolled

Direct Oral Anticoagulants in Patients With Atrial Fibrillation (DOACs vs DOACs)

Completed·CCanadian Network for Observational Drug Effect Studies, CNODES··NCT03568916·227,579 enrolled

Study to Learn More About the Benefits and Side-effects of Drugs Rivaroxaban and Apixaban Compared to the Drug Warfarin for Stroke Prevention in Patients With Rapid and Irregular Heartbeat Which is Not Due to a Heart-valve Fault (Non-valvular Atrial Fibrillation) in the UK Routine Clinical Practice

Completed· Bayer logo

Bayer··NCT03847181·45,164 enrolled

A Nationwide Observational Study Looking at Effectiveness and Bleeding Complications of NOACs vs. VKA in Non-valvular Atrial Fibrillation Patients.

Terminated· Bayer logo

Bayer··NCT03715725·70,000 enrolled

Venous Thromboembolism16 trials

Venous Thromboembolism in Renally Impaired Patients and Direct Oral Anticoagulants

Terminated·—·Phase 3·NCT02664155·203 enrolled

Oral Anticoagulant Apixaban for Treatment of Venous Thromboembolism

Completed·NNew York Medical College·Phase 2·NCT04041843·25 enrolled

Improved Adherence With Extended Venous Thromboembolism Prophylaxis After Major Cancer Surgery

Completed·MMcMaster University·Phase 4·NCT04479579·53 enrolled

Show 13 more trials

Treatment Patterns Among Patients With Venous Thromboembolism in the United States

Completed· Pfizer logo

Pfizer··NCT05795062·13,945 enrolled

Monotherapy Anticoagulation To Expedite Home Treatment of Venous Thromboembolism

Completed·IIndiana University··NCT03404635·1,300 enrolled

Apixaban for the Treatment of Venous Thromboembolism in Patients With Cancer

Completed·FFadoi Foundation, Italy·Phase 3·NCT03045406·1,170 enrolled

Anticoagulation Strategies for Acute Venous Thromboembolism in Patients With End-Stage Renal Disease Using USRDS Data

Completed·JJohns Hopkins University··NCT04818151·14,914 enrolled

An Observational Study Called H2H-OSCAR-US to Learn More About How Well Rivaroxaban Works and How Safe it is Compared to Apixaban Under Real World Conditions in People in the US With Cancer Who Have Problems Due to Formation of Blood Clots in the Veins (Venous Thromboembolism)

Completed· Bayer logo

Bayer··NCT05461807·2,437 enrolled

A Randomized Phase II Open Label Study to Compare the Safety and Efficacy of Subcutaneous Dalteparin Versus Direct Oral Anticoagulants for Cancer-associated Venous Thromboembolism

Unknown status·—·Phase 2·NCT03139487·176 enrolled

Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism

Completed·—·Phase 3·NCT02585713·300 enrolled

Venous Thromboembolism Prevention in Outpatients With Glioma

Recruiting·UUniversity of Vermont Medical Center·Phase 2·NCT05683808·40 enrolled

Apixaban for the Prevention of Venous Thromboembolism in Cancer Patients

Completed·OOttawa Hospital Research Institute·Phase 2·NCT02048865·575 enrolled

Treatment Patterns and Bleeding Risk of Anticoagulants in Patients With Venous Thromboembolism in Korea

Completed· Pfizer logo

Pfizer··NCT05022563·55,759 enrolled

Study to Gather Information How Often Venous Thromboembolism Occurs in Prostate Cancer Patients in Sweden and How This Condition is Treated With Blood Thinners

Completed· Bayer logo

Bayer··NCT03965741·97,765 enrolled

Extended-Duration Low-Intensity Apixaban to Prevent Recurrence in High-Risk Patients With Provoked Venous Thromboembolism

Completed·—·Phase 4·NCT04168203·600 enrolled

Direct Oral Anticoagulants and Venous Thromboembolism

Completed·CCanadian Network for Observational Drug Effect Studies, CNODES··NCT02833987·59,525 enrolled

Anticoagulant7 trials

Pharmacokinetics and Point of Care Testing of Direct Oral Anticoagulants Subjects

Unknown status·DDoasense GmbH·Phase 1·NCT05491460·24 enrolled

Replication of the ARISTOTLE Anticoagulant Trial in Healthcare Claims Data

Completed·—··NCT04593030·220,518 enrolled

Prediction of the COBRRA AF Anticoagulant Trial in Healthcare Claims Data

Completed·—··NCT05256797·353,980 enrolled

Show 4 more trials

Use of Direct Oral Anticoagulants in UK

Completed· Bayer logo

Bayer··NCT03119116·31,336 enrolled

Start or STop Anticoagulants Randomised Trial (SoSTART)

Completed·UUniversity of Edinburgh·Phase 3·NCT03153150·203 enrolled

Replication of the AMPLIFY Anticoagulant Trial in Healthcare Claims Data

Completed·—··NCT04736719·19,002 enrolled

Prediction of the COBRRA VTE Anticoagulant Trial in Healthcare Claims Data

Completed·—··NCT05264168·41,875 enrolled

COVID-196 trials

FREEDOM COVID-19 Anticoagulation Strategy

Completed·VValentin Fuster·Phase 4·NCT04512079·3,460 enrolled

Effect of Prophylactic and Therapeutic Anticoagulants in Egyptian Patients With COVID-19

Completed·—··NCT04736901·90 enrolled

HElping Alleviate the Longer-term Consequences of COVID-19 (HEAL-COVID)

Unknown status·—·Phase 3·NCT04801940·2,631 enrolled

Show 3 more trials

COVID-19 Thrombosis Prevention Trials: Post-hospital Thromboprophylaxis

Completed·—·Phase 3·NCT04650087·1,291 enrolled

COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80

Terminated·FFrank C Sciurba·Phase 3·NCT04498273·657 enrolled

Apixaban for PrOphyLaxis of thromboemboLic Outcomes in COVID-19

Terminated·—·Phase 4·NCT04746339·411 enrolled

Stroke4 trials

Eliquis Acute Stroke Safety Evaluation

Completed·UUniversity of Alberta··NCT04435418·100 enrolled

Anticoagulation in ICH Survivors for Stroke Prevention and Recovery

Recruiting·YYale University·Phase 3·NCT03907046·700 enrolled

Apixaban for Treatment of Embolic Stroke of Undetermined Source

Completed·UUniversity Hospital Tuebingen·Phase 3·NCT02427126·352 enrolled

Show 1 more trial

MidregiOnal Proatrial Natriuretic Peptide to Guide SEcondary Stroke Prevention

Unknown status·UUniversity of Zurich·Phase 3·NCT03961334·620 enrolled

81 more indications

Interaction4 trials

Phase 1 Drug Interaction Study of Apixaban and Atenolol in Healthy Subjects

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT02262533·15 enrolled

Drug Interaction Study of Apixaban With Cyclosporine and Tacrolimus

Completed·TThomas Jefferson University·Phase 1·NCT03083782·12 enrolled

Phase 1 Drug Interaction Study of the Effect of Apixaban on the PK of Digoxin in Healthy Subjects

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT02262520·24 enrolled

Show 1 more trial

PK and PD Interaction Between Tegoprazan and NOACs After Multiple Oral Dosing in Healthy Volunteers

Completed·HHK inno.N Corporation·Phase 1·NCT05723510·87 enrolled

Deep Vein Thrombosis4 trials

Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary Embolism

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT00633893·2,711 enrolled

Efficacy and Safety Study of Apixaban for the Treatment of Deep Vein Thrombosis or Pulmonary Embolism

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT00643201·5,614 enrolled

AStudy To Evaluate Safety And Eficacy Of Apixaban In Japanese Acute Deep Vein Thrombosis (DVT) And Pulmonary Embolism (PE) Patients

Completed· Pfizer logo

Pfizer·Phase 3·NCT01780987·80 enrolled

Show 1 more trial

Calf Deep Vein Thrombosis Treatment Trial

Terminated·MMayo Clinic·Phase 4·NCT03590743·5 enrolled

Portal vein thrombosis4 trials

Apixaban, Warfarin and Aspirin Prevents Portal Vein Thrombosis in Patients After Laparoscopic Splenectomy（ESAWAAPT）

Completed·NNorthern Jiangsu People's Hospital·Phase 4·NCT04645550·120 enrolled

Efficacy of Apixaban in the Treatment of Portal Vein Thrombosis Occurring More Than One Year After LS

Recruiting·NNorthern Jiangsu People's Hospital·N/A·NCT07461545·40 enrolled

Apixaban Prevents Portal Vein Thrombosis After Laparoscopic Splenectomy and Azygoportal Disconnection

Completed·NNorthern Jiangsu People's Hospital·N/A·NCT05304455·40 enrolled

Show 1 more trial

Efficacy of Apixaban in Treating Portal Vein Thrombosis Occurring More Than One Year After LSD

Recruiting·NNorthern Jiangsu People's Hospital·N/A·NCT07461532·40 enrolled

Acute Coronary Syndrome3 trials

A Study to Evaluate the Safety of Apixaban in Acute Coronary Syndrome (ACS) Japanese Patients

Terminated· Pfizer logo

Pfizer·Phase 2·NCT00852397·151 enrolled

Safety Study of Apixaban in Recent Acute Coronary Syndrome

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT00313300·1,741 enrolled

Phase III Acute Coronary Syndrome

Terminated· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT00831441·7,484 enrolled

Anticoagulation3 trials

AntiCoagulation Versus AcetylSalicylic Acid After Transcatheter Aortic Valve Implantation

Recruiting·OOslo University Hospital·Phase 3·NCT05035277·360 enrolled

Reversibility of Apixaban Anticoagulation With the Four Factor Prothrombin Complex Concentrate Kcentra

Completed·TThomas Jefferson University·Phase 1·NCT02270918·12 enrolled

DOAC - Dosing Options in AntiCoagulation Prophylaxis

Recruiting·UUniversity of Vermont·Phase 3·NCT07005024·996 enrolled

Thrombosis3 trials

Oral Direct Factor Xa-inhibitor Apixaban in Patients With Acute Symptomatic Deep-vein Thrombosis-The Botticelli DVT Study

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT00252005·520 enrolled

The API-CALF Study: Apixaban to Treat Calf Vein Thrombosis

Not yet recruiting·UUniversity Hospital, Geneva·Phase 3·NCT04981327·1,300 enrolled

Avoiding Risks of Thrombosis and Bleeding in Surgery (ARTS) Trial

Recruiting·CClinical Urology and Epidemiology Working Group·Phase 4·NCT06523959·5,436 enrolled

Venous thrombosis3 trials

Apixaban for Routine Management of Upper Extremity Deep Venous Thrombosis

Terminated·IIntermountain Health Care, Inc.·Phase 4·NCT02945280·52 enrolled

Apixaban as Treatment of Venous Thrombosis in Patients With Cancer: The CAP Study

Completed·UUniversity Hospital, Akershus·Phase 4·NCT02581176·300 enrolled

Efficacy of Apixaban in Malignancy With Deep Venous Thrombosis

Unknown status·—·Phase 3·NCT04462003·100 enrolled

TED3 trials

Bioequivalence Study of Apixaban 5 mg Film-Coated Tablet

Completed·DDexa Medica Group·Phase 1·NCT06817811·24 enrolled

Pivotal BE Study of TAH3311 ODF vs ELIQUIS® Tablet Under Fasted Condition in Healthy Volunteers

Completed·TTAHO Pharmaceuticals Ltd.·Phase 2·NCT06689436·60 enrolled

Bioequivalence Study of Apixaban 5 mg Film-coated Tablets in Healthy Thai Volunteers

Not yet recruiting·IInternational Bio service·Phase 1·NCT06388239·28 enrolled

Tics2 trials

A Healthy Volunteer Pharmacokinetics (PK)/Pharmacodynamics (PD), Safety and Tolerability Study of Andexanet in Healthy Japanese and Caucasian Subjects

Completed·PPortola Pharmaceuticals·Phase 2·NCT03310021·108 enrolled

Effect of Clarithromycin on the Pharmacokinetics of Apixaban in Healthy Participants

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT02912234·20 enrolled

Thrombocytopenia2 trials

Apixaban in Thrombocytopenia

Recruiting·RRushad Patell·Phase 1·NCT06886516·30 enrolled

Efficacy and Safety of Apixaban in the Treatment of Heparin Induced Thrombocytopenia (HIT)

Terminated·MMassachusetts General Hospital·Phase 2·NCT03594045·5 enrolled

Pulmonary Embolism2 trials

Standard-dose Apixaban AFtEr Very Low-dose ThromboLYSis for Acute Intermediate-high Risk Acute Pulmonary Embolism

Terminated·—·Phase 4·NCT03988842·4 enrolled

Sidlenafil in Combination With Oral Anticoagulants in Patients With Intermediate-high Risk of Pulmonary Embolism

Unknown status·MMeshalkin Research Institute of Pathology of Circulation·Phase 1·NCT02946944·100 enrolled

Prophylaxis2 trials

THRomboprophylaxis in Individuals Undergoing Superficial endoVEnous Treatment (THRIVE)

Recruiting·IImperial College London·Phase 4·NCT05735639·6,660 enrolled

Oral Apixaban (Eliquis) Versus Enoxaparin (Lovenox) for Thromboprophylaxis in Women With Suspected Pelvic Malignancy

Completed·UUniversity of Colorado, Denver·Phase 2·NCT02366871·400 enrolled

Hemodialysis2 trials

Low-Dose Apixaban Added to Standard Heparin Lock Versus Heparin Lock Alone to Prevent Tunneled Hemodialysis Catheters Dysfunction (APICATH-HD)

Not yet recruiting·HHospital Civil de Guadalajara·Phase 4·NCT07404345·54 enrolled

Pharmacokinetics and Pharmacodynamics of Apixaban in Subjects on Hemodialysis

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT01340586·18 enrolled

Left Ventricular Thrombus2 trials

Apixaban in Patients With Left Ventricular Thrombus

Completed·SSaud Al Babtain Cardiac Center·Phase 3·NCT05208398·50 enrolled

Apixaban Versus Warfarin in Patients With Left Ventricular Thrombus

Completed·UUniversiti Sains Malaysia·Phase 3·NCT02982590·27 enrolled

Oral2 trials

Comparative Bioavailability Study of TAH3311 5 mg Oral Dissolving Film vs ELIQUIS® 5 mg Tablet in Healthy Volunteers

Completed·TTAHO Pharmaceuticals Ltd.·Phase 1·NCT05995119·12 enrolled

Evaluation of the Hemocompatibility of the Direct Oral Anti-Coagulant Apixaban in Left Ventricular Assist Devices

Completed·PPalak Shah·Phase 2·NCT04865978·30 enrolled

Effectiveness2 trials

The Safety and Effectiveness of Warfarin Vs Apixaban in Patients with NVAF/ VTE and ESKD on Dialysis

Completed·AAbu Dhabi Health Services Company··NCT06606275·67 enrolled

Real-world Comparative Effectiveness of Apixaban Versus Vitamin K Antagonist

Completed· Bayer logo

Bayer··NCT02687854·18,591 enrolled

Heavy Menstrual Bleeding2 trials

RAMBLE - Rivaroxaban vs. Apixaban for Heavy Menstrual Bleeding

Completed·IIndiana University·Phase 2/3·NCT02829957·19 enrolled

Prospective Comparison of Incidence of Heavy Menstrual Bleeding in Women Treated With Direct Oral Anticoagulants

Completed·CCardioangiologisches Centrum Bethanien··NCT04477837·84 enrolled

Complication2 trials

Complications and Antiplatelet and Anticoagulant Therapy in Vascular Surgery.

Active, not recruiting·PPetrovsky National Research Centre of Surgery··NCT07358416·500 enrolled

NOACs in Oral and Maxillofacial Surgery: Impact on Post-operative Complications

Completed·MMalmö University··NCT04662515·216 enrolled

Trial2 trials

The Nordic Aortic Valve Intervention Trial 4 (NOTION-4)

Active, not recruiting·RRigshospitalet, Denmark·N/A·NCT06449469·352 enrolled

PROACT Xa - A Trial to Determine if Participants With an On-X Aortic Valve Can be Maintained Safely on Apixaban

Terminated·AArtivion Inc.·Phase 3·NCT04142658·863 enrolled

Nephrotic Syndrome2 trials

Pharmacokinetics of Apixaban in Nephrotic Syndrome

Completed·UUniversity of North Carolina, Chapel Hill·Phase 1·NCT02599532·21 enrolled

A Prospective Multi-dose Study of Apixaban in Subjects With Nephrotic Syndrome

Completed·UUniversity of North Carolina, Chapel Hill·Phase 1·NCT04278729·22 enrolled

Phase 12 trials

Phase 1 Bioavailability Study of Apixaban Solution Formulation Relative to Apixaban Tablets in Healthy Subjects

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT02034565·48 enrolled

Phase 1 Oral Solution Bioavailability Study of Apixaban When Administered Through a Nasogastric Tube in Healthy Subjects

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT02034578·75 enrolled

Knee Replacement Surgery2 trials

Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Knee Replacement Surgery

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT00452530·3,221 enrolled

A Study to Evaluate the Safety and Efficacy of Intravenous JNJ-64179375 Versus Oral Apixaban in Participants Undergoing Elective Total Knee Replacement Surgery

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT03251482·308 enrolled

Myocardial Infarction1 trial

Apixaban Prophylaxis for Prevention of Left Ventricular Thrombus Following Anterior Myocardial Infarction

Recruiting·NNational Institute of Cardiovascular Diseases, Pakistan·Phase 3·NCT06742567·472 enrolled

Safety and Efficacy1 trial

Safety and Efficacy of Rivaroxaban and Apixaban in Comparison to Warfarin in Left Ventricular Clot- Clinical Trial

Unknown status·PPeshawar Institute of Cardiology·Phase 4·NCT05973188·141 enrolled

Vascular Access1 trial

Apixaban for Prevention of Post-angioplasty Thrombosis of Hemodialysis Vascular Access

Unknown status·NNational Taiwan University Hospital Hsin-Chu Branch·Phase 4·NCT04489849·150 enrolled

Age1 trial

Food Effect Study For Apixaban Commercial Image Tablets

Completed· Pfizer logo

Pfizer·Phase 1·NCT01437839·22 enrolled

Pancreaticoduodenectomy1 trial

Pharmacokinetics of Apixaban in Patients Undergoing Pancreaticoduodenectomy

Completed·TThomas Jefferson University·Phase 1·NCT04191928·4 enrolled

Adult Subject1 trial

A Study to Assess the Effects of 2 Prothrombin Complex Concentrates on the Pharmacodynamics of Apixaban in Healthy Adult Subjects

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT02074358·43 enrolled

Hematologic Malignancies1 trial

Reduced-Dose Apixaban and Rivaroxaban Versus Low-Molecular-Weight Heparin in Patients With Hematologic Malignancies

Recruiting·MMedical University of Gdansk·N/A·NCT07270263·100 enrolled

ESS1 trial

Expanded Access for Apixaban

Available· Bristol-Myers Squibb logo

Bristol-Myers Squibb··NCT05187286

Transplant Recipient1 trial

Drug Interaction Study of Apixaban With Cyclosporine or Tacrolimus in Transplant Recipients

Completed·UUniversity of Saskatchewan·Phase 4·NCT04023760·14 enrolled

Antiphospholipid Syndrome1 trial

Apixaban for Secondary Prevention of Thromboembolism Among Patients With AntiphosPholipid Syndrome

Completed·—·Phase 4·NCT02295475·48 enrolled

Heart1 trial

DOT HeartMate 3 Study

Completed·IInstitute for Clinical and Experimental Medicine·N/A·NCT04974684·45 enrolled

Aortic Stenosis1 trial

Anti-Thrombotic Strategy After Trans-Aortic Valve Implantation for Aortic Stenosis

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT02664649·1,510 enrolled

Pediatric1 trial

Multiple-Dose Study Apixaban in Pediatric Subjects With an Indwelling Central Venous Catheter

Terminated· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT01195727·13 enrolled

Kidney Disease1 trial

Apixaban in End-stage Kidney Disease : A Pharmacokinetics Study

Completed·UUniversitaire Ziekenhuizen KU Leuven·Phase 2·NCT03456648·24 enrolled

Leukemia1 trial

A Study of the Safety and Effectiveness of Apixaban in Preventing Blood Clots in Children With Leukemia Who Have a Central Venous Catheter and Are Treated With Asparaginase

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT02369653·512 enrolled

Drug1 trial

Apixaban Dose Reduction in Patients With Elevated Drug Levels

Unknown status·HHamilton Health Sciences Corporation·Phase 2·NCT02809469·120 enrolled

Inflammatory Bowel Disease1 trial

Postoperative Extended Venous Thromboprophylaxis in Inflammatory Bowel Disease

Unknown status·MMcMaster University·Phase 1·NCT03935451·60 enrolled

Hemodiafiltration1 trial

Study of Apixaban in Patients Receiving Hemodiafiltration

Completed·HHospital Universitari de Bellvitge·Phase 2·NCT04952792·11 enrolled

Chronic Kidney Disease1 trial

Stroke Prophylaxis With Apixaban in Chronic Kidney Disease Stage 5 Patients With Atrial Fibrillation

Recruiting·RRegion Stockholm·Phase 3·NCT05679024·1,400 enrolled

MPA1 trial

Bioavailability Study Comparing Modified Release To Immediate Release Apixaban Tablets In Healthy Volunteers

Completed· Pfizer logo

Pfizer·Phase 1·NCT00914641·16 enrolled

Atrial Appendage1 trial

Apixaban vs Dual Antiplatet Therapy Study After Left Atrial Appendage Occlosure (ADALA)

Completed·DDR. XAVIER FREIXA·Phase 4·NCT05632445·160 enrolled

Hip Replacement Surgery1 trial

Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Hip Replacement Surgery (ADVANCE-3)

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT00423319·5,407 enrolled

Sickle Cell Disease1 trial

Apixaban in Patients With Sickle Cell Disease

Terminated·NNirmish Shah·Phase 3·NCT02179177·16 enrolled

Total Knee Arthroplasty1 trial

FactOr XIa inhibiTion for the pRevention of venOus Thromboembolism in Patients Undergoing Total Knee Arthroplasty

Completed· Bayer logo

Bayer·Phase 2·NCT03276143·813 enrolled

Bariatric Patients1 trial

Apixaban Pharmacokinetics in Bariatric Patients (APB)

Completed·JJohns Hopkins University·Phase 4·NCT02406885·33 enrolled

Treatment1 trial

A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE

Terminated·AAnthos Therapeutics, Inc.·Phase 3·NCT05171049·1,150 enrolled

Portal Hypertension1 trial

Apixaban for Intrahepatic Non Cirrhotic Portal Hypertension

Active, not recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT04007289·166 enrolled

Osteoporosis1 trial

The Effectiveness and Safety of Apixaban in NVAF Patients With History of Osteoporosis and/or Fracture: A Nation-wide Population Based Study

Withdrawn· Pfizer logo

Pfizer··NCT04198844

Heart Disease1 trial

A Study of the Safety and Pharmacokinetics of Apixaban Versus Vitamin K Antagonist (VKA) or Low Molecular Weight Heparin (LMWH) in Pediatric Subjects With Congenital or Acquired Heart Disease Requiring Anticoagulation

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT02981472·192 enrolled

Prevention1 trial

Study of Apixaban for the Prevention of Thrombosis-related Events in Patients With Acute Medical Illness

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT00457002·6,758 enrolled

Head and Neck Cancer1 trial

Apixaban or Enoxaparin After Head and Neck Cancer Surgery

Recruiting·KKiranya Arnold·Phase 4·NCT07189897·76 enrolled

Obese Patients1 trial

Effectiveness And Safety Of Oral Anticoagulants Among Obese Patients With Non-Valvular A-Fib In VA Patients With Medicare

Completed· Pfizer logo

Pfizer··NCT04681482·107,383 enrolled

Spinal Cord Injury1 trial

Apixaban For Thromboprophylaxis In Patients With Acute Spinal Cord Injury

Terminated·MMcMaster University·Phase 2·NCT03200613·8 enrolled

Post-Operative Atrial Fibrillation1 trial

Apixaban Versus Warfarin for the Management of Post-operative Atrial Fibrillation

Completed·SSanford Health·Phase 2/3·NCT02889562·56 enrolled

Efficacy and Safety1 trial

Efficacy and Safety of Apixaban in Reducing Restenosis and Limb Loss in PAD Patients.

Unknown status·SScience Valley Research Institute·Phase 3·NCT04229264·200 enrolled

Calcification1 trial

Apixaban Versus Warfarin in the Evaluation of Progression of Atherosclerotic Calcification and Vulnerable Plaque

Completed·LLundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center·Phase 4·NCT02090075·66 enrolled

Intracranial Hemorrhage1 trial

Restart TICrH Alpha Pilot Protocol, Restarting DOACs After Traumatic Intracranial Hemorrhage

Unknown status·UUniversity of Texas at Austin·Phase 3·NCT04891861·100 enrolled

Prevention of Thromboembolic Events1 trial

A Phase 2 Pilot Study of Apixaban for the Prevention of Thromboembolic Events in Patients With Advanced (Metastatic) Cancer

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT00320255·130 enrolled

Pilot Study1 trial

Apixaban in Patients Who Undergo CIED Procedure- Randomized Pilot Study

Withdrawn·MMayo Clinic·Phase 2·NCT02450682

Heart Failure1 trial

Effects of APIXaban on BRAIN Protection in Patients With Sinus Rhythm and Heart Failure: APIXBRAIN-HF Trial

Unknown status·KKorea University Guro Hospital·Phase 2·NCT04696120·200 enrolled

Direct Oral Anticoagulants (DOACs)1 trial

Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer

Completed·AAlliance Foundation Trials, LLC.·N/A·NCT02744092·811 enrolled

After Cardiac Surgery1 trial

DOAC Versus VKA After Cardiac Surgery

Withdrawn·LLaval University·Phase 2·NCT04002011

Tic Disorder1 trial

Study to Evaluate a Single Dose of Apixaban in Pediatric Participants at Risk for a Thrombotic Disorder

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT01707394·49 enrolled

Cohort Study1 trial

Non-interventional, Retrospective Cohort Study to Explore OAC Treatment in Korea

Completed· Pfizer logo

Pfizer··NCT03572972·64,684 enrolled

Phase 21 trial

Phase 2 Study of Apixaban Reversal by Ciraparantag as Measured by WBCT

Completed·AAMAG Pharmaceuticals, Inc.·Phase 2·NCT03288454·60 enrolled

Cerebrovascular Event1 trial

Apixaban Versus Dual-antiplatelet Therapy (Clopidogrel and Aspirin) in Acute Non-disabling Cerebrovascular Events

Unknown status·XXijing Hospital·Phase 2/3·NCT01924325·10,000 enrolled

Patent foramen ovale1 trial

Patients With Patent Foramen Ovale and Endocardial Device Leads on Apixaban for Prevention of Paradoxical Emboli

Withdrawn·MMayo Clinic·Phase 2·NCT02378623

Myeloma1 trial

Evaluation of the Use of Apixaban in Prevnetion of Thromboembolic Disease in Patients With Myeloma Trated With iMiDs

Completed·UUniversity Hospital, Grenoble·Phase 3·NCT02066454·108 enrolled

High Risk1 trial

Strategy of Continued Versus Interrupted Novel Oral Anti-coagulant at Time of Device Surgery in Patients With Moderate to High Risk of Arterial Thromboembolic Events

Completed·OOttawa Heart Institute Research Corporation·Phase 3·NCT01675076·663 enrolled

Venous malformation1 trial

A Study of Direct Oral Anticoagulants in Patients with Painful Venous Malformations with Localized Intravascular Coagulation

Not yet recruiting·OOslo University Hospital·Phase 2·NCT06729034·20 enrolled

Adult1 trial

Bioequivalence Study of Two Products of Apixaban 5mg Tablets in Healthy, Adult, Human Subjects

Completed·HHumanis Saglık Anonim Sirketi·Phase 1·NCT06043297·30 enrolled

Oral Anticoagulation1 trial

DIrect Oral Anticoagulation and Bioprothesis Aortic Valve

Not yet recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT05687448·1,500 enrolled

Myeloproliferative Neoplasm1 trial

Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients

Completed·OOttawa Hospital Research Institute·Phase 2·NCT04243122·44 enrolled

Breast Reconstruction1 trial

Apixaban vs Enoxaparin Following Microsurgical Breast Reconstruction-An RCT

Completed·SStanford University·Phase 1/2·NCT04504318·82 enrolled

Intracerebral Haemorrhage1 trial

Avoiding Anticoagulation After IntraCerebral Haemorrhage

Recruiting·UUniversity Hospital, Lille·Phase 3·NCT03243175·300 enrolled

Cirrhosis1 trial

DOAC in Patients with Child a or B Liver Cirrhosis

Recruiting·—·Phase 2·NCT05869591·40 enrolled

Peritoneal Dialysis1 trial

Apixaban in Subjects With Peritoneal Dialysis

Completed·UUniversity Hospital, Caen·Phase 1·NCT04006093·24 enrolled

PK/PD1 trial

A Healthy Volunteer PK/PD, Safety and Tolerability Study of Second Generation Andexanet Alfa

Completed·PPortola Pharmaceuticals·Phase 1·NCT03083704·153 enrolled

Unspecified11 trials

Bioavailability of Apixaban Crushed Tablet

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT02101112·69 enrolled

The DARE Warfarin CER Study

Unknown status·—··NCT03271450·416,000 enrolled

Medical Need of OAC Reversal

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim··NCT03254147·53,969 enrolled

Show 8 more trials

Early Post-Marketing Study of ELIQUIS (Apixaban) in Mexico

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb··NCT02345343·100 enrolled

Early Post-marketing Study of Eliquis (Apixaban)

Withdrawn· Bristol-Myers Squibb logo

Bristol-Myers Squibb··NCT02153424

Eliquis Regulatory Post Marketing Surveillance (rPMS)

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb··NCT01885585·100 enrolled

NOAC Portuguese Real World Study

Withdrawn· Pfizer logo

Pfizer··NCT04808934

Eliquis Regulatory Post Marketing Surveillance

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb··NCT01885598·3,335 enrolled

Apixaban VS Warfarin in AF Pts First Three Months After Repair or BIO AVR MVR

Not yet recruiting·MMeshalkin Research Institute of Pathology of Circulation·Phase 3·NCT07434661·120 enrolled

A Multi-center Study of Apixaban(APPROACH)

Unknown status·SShanghai Zhongshan Hospital··NCT04550637·200 enrolled

Apixaban Versus Warfarin in Patients With Left Ventricular (LV) Thrombus

Completed·HHadassah Medical Organization·Phase 3·NCT03232398·40 enrolled

Regulatory

FDA Approval Timeline[5]

Apr 17, 2025

ELIQUIS SPRINKLE

NDA NDA220073

Apr 17, 2025

ELIQUIS

NDA NDA202155

Sources

References

[1]
ClinicalTrials.gov — 265 trial records for Apixaban. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Eliquis drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Apixaban compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Apixaban. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA220073). U.S. Food & Drug Administration.
[6]
FDA Orange Book — Patent and exclusivity data for Eliquis. U.S. Food & Drug Administration.
[7]
SEC EDGAR — Bristol-Myers Squibb company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Coagulation Factor X Inhibitor[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: Bristol-Myers Squibb

Patent Landscape[6]

Patent Cliff

Nov 21, 2026

Earliest patent expiration — generic entry possible after this date

Patent #Expires

6967208Nov 21, 2026

6967208*PEDMay 21, 2027

9326945Feb 24, 2031

9326945*PEDAug 24, 2031

11896586Nov 22, 2040

1 more patents

11896586*PEDMay 22, 2041